ActiveCare+S.F.T.® is the only system on the market that allows you to refrain from using anticoagulants in DVT prophylaxis for your patients. This system is the only non-pharmaceutical mechanical solution that provides your patient continuous 24/7 protection throughout the time of high risk, both in-hospital and post-acute care.
-
The S.A.F.E. Study
ActiveCare+S.F.T.® was recently compared with Enoxaparin in a prospective randomized clinical trial that took place in 9 leading US medical centers, known as the S.A.F.E. study: (SFT Alternative For Enoxaparin). The S.A.F.E. Study is the first (and only known study to MCS) which compares head to head a device to enoxaparin, with endpoints defined as VTE and bleeding complications in both acute and post-acute care settings.
-
Efficacy & Safety
ActiveCare+S.F.T.
®
has been tested in a series of
clinical studies
in leading institutions.
To view the complete study, visit our
S.A.F.E. Study page.
-
S.F.T. Technology
The ActiveCare+S.F.T.® system is based on Synchronized Flow Technology (S.F.T.). This new technology enables the synchronization of the device compression to a specific phase of the respiratory related venous phasic flow. As a result, a significantly high pulsatile flow is achieved reaching a high peak venous velocity at the common femoral vein.
-
Ease of Use & Compliance
The miniature size and portability of the ActiveCare+S.F.T.® system, provides Continuous Enhanced Circulation Therapy (C.E.C.T.) to the patient with a high compliance rate at both acute care and post-discharge, delivering 24/7 treatment.
